Opus Genetics (NASDAQ:IRD) Stock Rating Upgraded by Zacks Research

Opus Genetics (NASDAQ:IRD) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Several other equities research analysts also recently weighed in on the company. Royal Bank Of Canada lowered their price target on Opus Genetics from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Friday, August 7th. Guggenheim began coverage on shares of Opus Genetics in a report on Thursday, June 4th. They set a “buy” rating and a $16.00 price objective on the stock. Citigroup began coverage on shares of Opus Genetics in a research report on Tuesday, April 28th. They issued an “outperform” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Opus Genetics in a research note on Friday, July 17th. Finally, BTIG Research reissued a “buy” rating and set a $12.00 target price on shares of Opus Genetics in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Opus Genetics presently has an average rating of “Moderate Buy” and a consensus target price of $10.69.

Opus Genetics Trading Down 3.1%

Shares of IRD opened at $3.76 on Tuesday. The firm has a market cap of $310.76 million, a PE ratio of -2.79 and a beta of 0.59. Opus Genetics has a 12 month low of $1.04 and a 12 month high of $5.81. The stock has a fifty day moving average price of $3.79 and a 200-day moving average price of $4.15.

Opus Genetics (NASDAQ:IRD) last announced its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%.The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $2.63 million. As a group, research analysts forecast that Opus Genetics will post -1.05 EPS for the current year.

Insider Transactions at Opus Genetics

In related news, Director Fighting Blindness Foundation sold 1,700,000 shares of Opus Genetics stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $4.35, for a total transaction of $7,395,000.00. Following the completion of the sale, the director owned 3,792,171 shares of the company’s stock, valued at $16,495,943.85. The trade was a 30.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO George Magrath sold 9,475 shares of Opus Genetics stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total value of $27,951.25. Following the sale, the chief executive officer directly owned 1,731,869 shares of the company’s stock, valued at $5,109,013.55. This trade represents a 0.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 1,729,331 shares of company stock valued at $7,481,629. 11.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Opus Genetics

A number of institutional investors have recently bought and sold shares of IRD. BlackRock Inc. acquired a new stake in Opus Genetics during the 2nd quarter valued at approximately $12,809,000. Balyasny Asset Management L.P. acquired a new stake in shares of Opus Genetics in the fourth quarter worth $5,463,000. Millennium Management LLC acquired a new stake in shares of Opus Genetics in the fourth quarter worth $4,025,000. ADAR1 Capital Management LLC raised its holdings in shares of Opus Genetics by 4,522.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,849,004 shares of the company’s stock worth $8,413,000 after purchasing an additional 1,809,004 shares during the last quarter. Finally, Nantahala Capital Management LLC raised its holdings in shares of Opus Genetics by 42.9% during the fourth quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock worth $9,610,000 after purchasing an additional 1,435,407 shares during the last quarter. 14.97% of the stock is owned by hedge funds and other institutional investors.

Opus Genetics News Roundup

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Analysts raised earnings estimates: Brookline Capital Markets lifted its projections for Q3 2026 EPS to $(0.15) from $(0.18), FY2026 EPS to $(0.87) from $(1.31), FY2027 EPS to $(0.56) from $(0.77), and FY2028 EPS to $(0.61) from $(0.68). These revisions indicate expectations for narrower losses. Opus Genetics analyst estimates
• Positive Sentiment: HC Wainwright remains bullish: The firm raised its Q4 2026 EPS forecast to $(0.09) from $(0.14), increased its FY2026 estimate to $(1.03) from $(1.18), and raised FY2027 expectations to $(0.40) from $(0.46). It maintains a Buy rating and an $8 price target, well above the stock’s recent trading level.
• Positive Sentiment: Long-term profitability is projected: HC Wainwright forecasts positive EPS of $0.05 in FY2029 and $0.27 in FY2030, while Brookline projects $0.62 in FY2030. These estimates support a potential long-term recovery if Opus successfully advances its pipeline and controls spending.
• Neutral Sentiment: Short-interest data provides little signal: Reported short interest was zero shares with a zero-day days-to-cover ratio, suggesting the data is incomplete or unreliable rather than indicating meaningful investor positioning.
• Negative Sentiment: Losses remain substantial: Analysts still expect Opus Genetics to post a full-year loss of approximately $(1.05) to $(1.09) per share. The latest quarter also showed very low revenue of $0.76 million versus a $2.63 million consensus estimate, despite a modest EPS beat.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.